Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer

NCT00091026 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

143

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions

BIOLOGICAL: cetuximab
DRUG: gemcitabine hydrochloride
BIOLOGICAL: bevacizumab
DRUG: erlotinib hydrochloride

Sponsor

National Cancer Institute (NCI)